Literature DB >> 33732333

A novel mutation in GP1BA gene in a family with autosomal dominant Bernard Soulier syndrome variant: A case report.

Jingyao Ma1, Zhenping Chen1, Gang Li1, Hao Gu1, Runhui Wu1.   

Abstract

Classic Bernard-Soulier syndrome (BSS) is a rare form of autosomal recessive disorder that is caused by mutations in the GP1BA gene that encode the GPIb-V-IX complex, a receptor of von Willebrand factor. BSS characterized by macrothrombocytopenia and excessive bleeding. The present study reports a single case (18-month Chinese girl) diagnosed with BSS. The patient suffered mild thrombocytopenia, giant platelets and normal platelet aggregation. In addition, mild bleeding and thrombocytopenia were also indicated in thirteen family members, including the proband and her father. Gene sequence analysis identified a monoallelic missense mutation in GP1BA (c.97T>A), which encodes a p.C33R substitution in the N-terminal domain of glycoprotein (GP)Ibα that may disrupt the protein structure. To the best of our knowledge, this dominant variant has not been reported previously. BSS's autosomal dominant inheritance mode is rarely identified and can be easily misdiagnosed as immune thrombocytopenia. For patients with giant platelets, thrombocytopenia and positive family history, next-generation sequencing for inherited thrombocytopenia, especially disorders that are caused by mutations in glycoprotein Ib-IX-V complex, is required. Copyright: © Ma et al.

Entities:  

Keywords:  Bernard-Soulier syndrome; autosomal dominant variant; glycoprotein Ib platelet subunit alpha gene; next-generation sequencing

Year:  2021        PMID: 33732333      PMCID: PMC7903392          DOI: 10.3892/etm.2021.9791

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


Introduction

The Bernard-Soulier syndrome (BSS) is an extremely rare congenital disease that is characterized by macrothrombocytopenia and defective binding of platelets to the von Willebrand factor (vWF), which participates in the adherence of platelets to the vascular subendothelial layer (1). BSS disease pathogenesis lies in the expression of vWF receptor via the glycoprotein Ib-IX-V (GPIb-IX-V) complex (2). The GPIb-IX-V complex consists of four subunits, glycoprotein (GP)Ibα, GPIbβ, GPIX and GPV, which are encoded by glycoprotein Ib platelet subunit alpha (GP1BA), glycoprotein Ib platelet subunit beta (GP1BB), GP9 and GP5(3). Mutations that occur in GP1BA, GP1BB and GP9 may lead to BSS (4). The major subunit, GPIbα, holds an essential ligand-binding site for vWF within its N-terminal domain, and this features the leucine-rich repeat (LRR) (5,6). Pathogenic mutations in its GP1BA gene are classically inherited as a biallelic, autosomal recessive trait (4). A milder phenotype caused by monoallelic autosomal dominant inheritance that shares characters with BSS, including macrothrombocytopenia, has been previously reported (6-12). However, this aforementioned phenotype does not lead to severe bleeding or serious surgical or obstetric hemorrhage that is commonly seen in BSS. Therefore, the autosomal dominant variant of BSS can be easily misdiagnosed as immune thrombocytopenia (ITP) and managed with intravenous immunoglobulin and glucocorticoids, which are used as a first-line treatment for ITP (13,14). In the present case report, sequence analysis performed on an 18-month-old girl identified an NM_000173 c.97T>A (p.Cys33Arg) (p.C33R) heterozygous missense mutation in GP1BA. This specific mutation has not been previously reported and may further expand the information regarding mutations in BSS.

Case report

An 18-month-old girl with thrombocytopenia consulted the Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University (Beijing, China). A period of six months prior to admission to the department, the patient underwent a physical examination, which revealed a baseline platelet count of 31x109/l. Since this examination, the patient had no bleeding symptoms, including easy bruising, epistaxis, gingival bleeding and other symptoms as a result of internal bleeding. A peripheral blood smear indicated giant platelets and a reduction in platelet count. vWF antigen (vWF Ag) levels was 94.6% (42.0-140.8%), aggregation response of platelets after adenosine diphosphate (ADP) was 55% (55-90%), collagen was 62.1% (55-90%), arachidonic acid was 82.6% (55-90%) and ristocetin was including low concentration and [76.1% (55-90%); low concentation] and [2.6% (<3%); standard concentration], all of which were within the normal range. CBC, peripheral blood smear and platelet aggregation were performed on the patients parents, and the patients father shared a similar phenotype, including enlarged platelet size and normal aggregation rate of platelet as follows: Aggregation response of platelets after adenosine diphosphate (ADP) was 56.4% (55-90%), collagen was 72.3% (55-90%), arachidonic acid was 85.7% (55-90%) and ristocetin, including low concentration and standard concentration, was 66.7% (55-90%) and 1.3% (<3%) respectively. Considering the probability of inherited thrombocytopenia and abnormal morphology of platelets, DNA samples for genetic analysis were collected from her parents. Written consent from the patient's parents was obtained at the time of sample collection. The present study was performed with approval from the Ethics Committee of Beijing Children's Hospital (Beijing, China; reference no. 2020-Z-113). Approximately 2 ml peripheral blood of the patient, parents and one sibling were collected in new EDTA containing tubes (as anticoagulant) for genetic analysis. Exome sequencing of germline DNA samples was performed using a QIAamp DNA Mini kit (Qiagen, China Co., Ltd.), according to the manufacturer's protocol. Selected targeted genes that were associated with thrombocytopenia were analyzed using a gene capture strategy with a GenCap custom enrichment kit (MyGenostics, Inc.), following the manufacturer's protocol. The final enriched sequencing libraries were sequenced for paired-end reads of 150 bp using Illumina NovaSeq 6000 platform (Illumina, Inc.). The identified variants were annotated using ANNOtate VARiation (ANNOVAR; http://annovar.openbioinformatics.org/en/latest/). The sequencing analysis identified a heterozygous nucleotide substitution in the GP1BA gene (NM_000173: exon2:c.97T>G). An amino acid of cysteine 33 was substituted with arginine in the N-terminal domain of GPIbα protein on the platelet membrane. A validation of GP1BA sequencing was performed on the patient's parents and one sibling. The pedigree analysis (Fig. 1) indicated an autosomal-dominant mode of inheritance. The individuals father carried a similar heterozygous p.C33R variant, while her mother carried a wild-type sequence (Fig. 2). The structural effect of the sequence variant was predicted to be deleterious via in-silico analysis (Fig. 3), using the following software with default parameters: Mutation Taster (http://www.mutationtaster.org/), Sorting Intolerant From Tolerant (http://sift.jcvi.org/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and Genomic Evolutionary Rate Profiling (http://mendel.stanford.edu/SidowLab/downloads/gerp/index.html). According to the ACMG guidelines (15), the variant was classified as ‘likely pathogenic’, which confirmed BSS.
Figure 1

Proband's (V-1) family pedigree indicates mild bleeding and thrombocytopenia. Black star indicates the analysis of family members by next-generation sequencing.

Figure 2

Sanger sequencing showing the nucleotide of GP1BA at position 97 in the reference sequence as T. The proband and her father were heterozygous for the variant C, and her mother was wild-type. The red arrows indicate the site of the new mutation, and the blue arrow indicates the wild-type sequence. GP1BA, glycoprotein Ib platelet subunit alpha.

Figure 3

Crystal structure of the human N-terminal domain (~300 aa) of GPIbα. Cys33 of our patient was presented by colored spheres in the conserved N-terminal flank (amino acid 1-35), which had a role in binding to von Willebrand factor. GP, glycoprotein.

Discussion

In the current case report, a novel heterozygous c.97T>A substitution was reported in the GP1BA gene, which causes a Cys33Arg amino acid substitution. The mutation was annotated with ANNOVAR and the results demonstrated that it has not been recorded in the GnomAD (https://gnomad.broadinstitute.org/), 1000 Genomes (http://www.1000genomes.org/), ExAC database (16), the human gene mutation database (http://www.biobase-international.com/product/hgmd; http://www.hgmd.cf.ac.uk/ac), OMIM (https://www.omim.org/) or ClinVar databases (https://www.ncbi.nlm.nih.gov/clinvar/). To date, ~60 variants of GP1BA encoding GPIBα protein have been identified, and the majority of these are homozygous and contribute to symptoms of BSS (6,17). However, the symptoms of individuals in the pedigree of the current study seemed milder than the symptoms of individuals with classic homozygous BSS. Platelet aggregation of the present patients with heterozygous BSS (including the response to the low concentration of ristocetin) appeared normal despite giant platelets being identified in the results of the peripheral blood smear. Mutations in BSS may be missense, nonsense, frameshift, insertions or deletions, and these mutations can cause abnormality in GPIBα protein expression (18,19). The dominant inheritance of BSS remains relatively rare as only six variants have been previously identified, including the Bolzano variant (p. Ala172Val), which is the most frequent type in Italy (12). The remaining four heterozygous mutations were described in single families (6-12). The phenotype of monoallelic BSS, which is the same as that of the biallelic BSS in the degree of symptom presentation, may vary based on different genotypes and relevant changes in the expression and function of GPIbα (2). Mutations in the patient outlined in the current case report and her father were located in the conserved N-terminal flanking domain. The domain lies ahead of the LRR region of GP Ibα, which serves a role in the orientation of charged residues (6). All previously reported variants (p.Ala172Val, p.Asn57His, p.Tyr70Asp, p.Leu73Phe, p.Asn150Ser and p.Leu59Arg), which are located in the LRR region (amino acids 35-200), may lead to macrothrombocytopenia. This is due to the abnormal interaction of the cytoplasmic end of GPIbα protein with the actin-binding protein, which controls the normal process of megakaryocyte maturation, demarcation membrane system production and the size of the platelets (20,21). While the conserved N-terminal flanking region of GPIbα, where the novel mutation was discovered in the pedigree outlined the present study, may interact with C-terminal flanking (amino acid 201-268) and exhibit a weak influence on the binding of GPIbα to vWF that is induced by ristocetin or botrocetin, the mutations within the LRR caused a more significant change in the formation of GPIbα as well as a pronounced disturbance in ligand binding (22). BSS is commonly misdiagnosed with ITP and is subsequently treated with futile therapies, including glucocorticoids and immunoglobulins (14). BSS is a rare bleeding disorder that is accompanied by thrombocytopenia, and symptoms are less pronounced in the monoallelic phenotype of the disease (6,8). BSS shares similar clinical characteristics with ITP, such as mucocutaneous bleeding, negative family history and normal platelet aggregation (14). However, the identification of giant platelets in a peripheral blood smear may help clinicians make an accurate diagnosis. In the current case report, the patient and her father shared the same mutation and similar mild manifestation. Her mother carried a wild-type genotype and did not exhibit macrothrombocytopenia and bleeding. For those suspected of having BSS, gene sequencing should be performed, and symptoms such as abnormal levels of bleeding should be investigated throughout the family to encourage early diagnosis and subsequently, the establishment of effective treatment. In the present study, platelet immunophenotype and vWF-cofactor activity analysis (binding of VWF to recombinant mutated GPIb) could not be performed. Therefore, whether this novel dominant variant contributes to the reduced expression of GPIb-V-IX and whether the inactive interaction between platelets and vWF was indicated, which is commonly identified in classic BSS, was not confirmed. Identification of the effect of specific mutations on the structure and function of GPIbα protein and the pathogenesis to a milder phenotype is required in future studies. A novel autosomal dominant inheritance mutation in GP1BA was identified in a family with mild bleeding symptoms and macrothrombocytopenia. This monoallelic mutation that occurs in the N-terminal flanking domain has, to the best of our knowledge, not been previously reported. Due to common misdiagnosis, gene sequencing is considered essential and urgent for diagnosing suspected patients who exhibit a blood smear showing giant platelets, with BSS.
  22 in total

Review 1.  Bernard-Soulier syndrome.

Authors:  J A López; R K Andrews; V Afshar-Kharghan; M C Berndt
Journal:  Blood       Date:  1998-06-15       Impact factor: 22.113

2.  A new heterozygous mutation in GP1BA gene responsible for macrothrombocytopenia.

Authors:  Dorsaf Ghalloussi; Noémie Saut; Denis Bernot; Xavier Pillois; Philippe Rameau; Gérard Sébahoun; Marie-Christine Alessi; Hana Raslova; Véronique Baccini
Journal:  Br J Haematol       Date:  2017-10-30       Impact factor: 6.998

Review 3.  The platelet glycoprotein Ib-IX complex.

Authors:  J A López
Journal:  Blood Coagul Fibrinolysis       Date:  1994-02       Impact factor: 1.276

Review 4.  Structural determinants within platelet glycoprotein Ibalpha involved in its binding to von Willebrand factor.

Authors:  N Cauwenberghs; K Vanhoorelbeke; S Vauterin; H Deckmyn
Journal:  Platelets       Date:  2000-11       Impact factor: 3.862

5.  Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome.

Authors:  A Savoia; C L Balduini; M Savino; P Noris; M Del Vecchio; S Perrotta; S Belletti; A Iolascon
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

6.  Novel point mutation in a leucine-rich repeat of the GPIbalpha chain of the platelet von Willebrand factor receptor, GPIb/IX/V, resulting in an inherited dominant form of Bernard-Soulier syndrome affecting two unrelated families: the N41H variant.

Authors:  Silvia Vettore; Raffaella Scandellari; Stefano Moro; Anna Maria Lombardi; Margherita Scapin; Maria Luigia Randi; Fabrizio Fabris
Journal:  Haematologica       Date:  2008-09-24       Impact factor: 9.941

Review 7.  The organizing principle of the platelet glycoprotein Ib-IX-V complex.

Authors:  R Li; J Emsley
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

Review 8.  Glycoprotein Ib-IX-V.

Authors:  R K Andrews; E E Gardiner; Y Shen; J C Whisstock; M C Berndt
Journal:  Int J Biochem Cell Biol       Date:  2003-08       Impact factor: 5.085

9.  Novel heterozygous missense mutation in the second leucine rich repeat of GPIbalpha affects GPIb/IX/V expression and results in macrothrombocytopenia in a patient initially misdiagnosed with idiopathic thrombocytopenic purpura.

Authors:  Shinji Kunishima; Toshi Imai; Motohiro Hamaguchi; Hidehiko Saito
Journal:  Eur J Haematol       Date:  2006-04       Impact factor: 2.997

Review 10.  Inherited thrombocytopenias frequently diagnosed in adults.

Authors:  C L Balduini; A Savoia; M Seri
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

View more
  1 in total

1.  A GP1BA Variant in a Czech Family with Monoallelic Bernard-Soulier Syndrome.

Authors:  Magdalena Skalníková; Kateřina Staňo Kozubík; Jakub Trizuljak; Zuzana Vrzalová; Lenka Radová; Kamila Réblová; Radka Holbová; Terézia Kurucová; Hana Svozilová; Jiří Štika; Ivona Blaháková; Barbara Dvořáčková; Marie Prudková; Olga Stehlíková; Michal Šmída; Leoš Křen; Petr Smejkal; Šárka Pospíšilová; Michael Doubek
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.